Patent US3553398A successfully refreshed from Google Patents.
Patent US4874748A successfully refreshed from Google Patents.
US4874748A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cloning vectors for streptomyces and use thereof in macrolide antibiotic production
Assignee: Abbott Laboratories
•
Filing: 1986-03-24
•
Granted: 1989-10-17
•
Expires: 2006-03-24
Abstract
Abstract DNA cloning shuttle vectors, including a cosmid shuttle vector, for E. coli and Streptomyces are disclosed. Specifically, disclosed shuttle vectors pAL7002 (NRRL B-18055) and pNJl (NRRL B-18054) contain an E. coli origin of replication, Streptomyces replication functions, and antibiotic resistance markers for both E. coli and Streptomyces. In addition, pNJl contains a cos sequence. Novel 2-norerythromycin antibiotics A, B, C, and D, which were produced in a strain Streptomyces erythreus 12693-240 (NRRL B-18053) transformed by pNJl bearing DNA from Streptomyces antibioticus, are also disclosed. The present invention also provides a method for producing novel antibiotics. This method for antibiotic production is applied to the transformation of a blocked mutant of S. erythreus with genomic DNA from S. antibioticus but may be more broadly applied to genes to antibiotic-producing strains transformed into cells which are blocked in the pathway for production of a different antibiotic.
Inventors
- 👤 Leonard Katz
- 👤 James Tuan
- 👤 James B. McAlpine
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 04:12
CPC Classifications
C; C07; C07H; C07H17/00; C07H17/04; C07H17/08; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/52; C12N15/63; C12N15/64; C12N15/74; C12N15/76; C12P; C12P19/00; C12P19/44; C12P19/60; C12P19/62; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/886
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
18 words
The compound 2-norerythromycin A, which is a compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
18 words
The compound 2-norerythromycin A, which is a compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
26 words
2-norerythromycin A as recited in claim 1 wherein said 2norerythromycin A in substantially pure form has a mass spectrum, FAB ion MH + m/z of 720.
Claim 4
Dependent Claim
12 words
The compound 2-norerythromycin B, which is a compound of the formula: ##STR2##
Claim 5
Dependent Claim
12 words
The compound 2-norerythromycin B, which is a compound of the formula: ##STR2##
Claim 6
Dependent Claim
27 words
2-norerythromycin B as recited in claim 3 wherein said 2-norerythromycin B in substantially pure form has a mass spectrum, FAB positive ion MH + m/z of 704.
Claim 7
Dependent Claim
18 words
The compound 2-norerythromycin C, which is a compound of the formula: ##STR3## or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
18 words
The compound 2-norerythromycin C, which is a compound of the formula: ##STR3## or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
40 words
2-norerythromycin C as recited in claim 5 wherein said 2-norerythromycin C in substantially pure form has an FAB positive ion MH+ m/z of 706 and has an 1 H-NMR spectrum comprising the partial spectrum as set forth in Table 3.
Claim 10
Dependent Claim
18 words
The compound 2-norerythromycin D, which is a compound of the formula: ##STR4## or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
18 words
The compound 2-norerythromycin D, which is a compound of the formula: ##STR4## or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
38 words
2-norerythromycin D as recited in claim 7 wherein said 2-norerythromycin D in substantially pure form has an 1 H-NMR spectrum as set forth in Table 1 and has a 13 C-NMR spectrum as set forth in Table 2.
Claim 13
Dependent Claim
62 words
An antibiotic composition comprising: a diluent or carrier compatible with antibiotic activity; and an effective amount of an antibiotic selected from the group consisting of: 2-norerythromycin A: ##STR5## or a pharmaceutically acceptable salt thereof; 2-norerythromycin B: ##STR6## or a pharmaceutically acceptable salt thereof; 2-norerythromycin C: ##STR7## or a pharmaceutically acceptable salt thereof; and 2-norerythromycin D: ##STR8## or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
62 words
An antibiotic composition comprising: a diluent or carrier compatible with antibiotic activity; and an effective amount of an antibiotic selected from the group consisting of: 2-norerythromycin A: ##STR5## or a pharmaceutically acceptable salt thereof; 2-norerythromycin B: ##STR6## or a pharmaceutically acceptable salt thereof; 2-norerythromycin C: ##STR7## or a pharmaceutically acceptable salt thereof; and 2-norerythromycin D: ##STR8## or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US3714142A
Cited
US4273875A
Cited
US4331803A
Cited
US4332900A
Cited
GB2107716A
Cited
GB2118947A
Cited
US4513085A
Cited
GB2107717A
Cited
US4740502A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-10-16 | 1993-04-17 | 1993-10-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-10-16 | 1997-04-17 | 1997-10-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-10-16 | 2001-04-17 | 2001-10-17 | $7700.00 | Window Closed / Lapsed |